Oyama N - Search Results

1

MicroPET assessment of androgenic control of glucose and acetate uptake in the rat prostate and a prostate cancer tumor model.

Oyama N, Kim J, Jones LA, Mercer NM, Engelbach JA, Sharp TL, Welch MJ. Oyama N, et al. Nucl Med Biol. 2002 Nov;29(8):783-90. doi: 10.1016/s0969-8051(02)00346-3. Nucl Med Biol. 2002. PMID: 12453586

2

11C-acetate PET imaging of prostate cancer: detection of recurrent disease at PSA relapse.

Oyama N, Miller TR, Dehdashti F, Siegel BA, Fischer KC, Michalski JM, Kibel AS, Andriole GL, Picus J, Welch MJ. Oyama N, et al. J Nucl Med. 2003 Apr;44(4):549-55. J Nucl Med. 2003. PMID: 12679398 Free article. Clinical Trial.

3

Monitoring of therapy in androgen-dependent prostate tumor model by measuring tumor proliferation.

Oyama N, Ponde DE, Dence C, Kim J, Tai YC, Welch MJ. Oyama N, et al. J Nucl Med. 2004 Mar;45(3):519-25. J Nucl Med. 2004. PMID: 15001697 Free article.

4

18F-fluoroacetate: a potential acetate analog for prostate tumor imaging--in vivo evaluation of 18F-fluoroacetate versus 11C-acetate.

Ponde DE, Dence CS, Oyama N, Kim J, Tai YC, Laforest R, Siegel BA, Welch MJ. Ponde DE, et al. Among authors: oyama n. J Nucl Med. 2007 Mar;48(3):420-8. J Nucl Med. 2007. PMID: 17332620 Free article.

5

Early response assessment in prostate carcinoma by ¹⁸F-fluorothymidine following anticancer therapy with docetaxel using preclinical tumour models.

Oyama N, Hasegawa Y, Kiyono Y, Kobayashi M, Fujibayashi Y, Ponde DE, Dence C, Welch MJ, Yokoyama O. Oyama N, et al. Eur J Nucl Med Mol Imaging. 2011 Jan;38(1):81-9. doi: 10.1007/s00259-010-1613-z. Epub 2010 Sep 29. Eur J Nucl Med Mol Imaging. 2011. PMID: 20878403

6

Monoclonal antibody RM2 as a potential ligand for a new immunotracer for prostate cancer imaging.

Hasegawa Y, Oyama N, Nagase K, Fujibayashi Y, Furukawa T, Murayama Y, Arai Y, Saito S, Welch MJ, Yokoyama O. Hasegawa Y, et al. Among authors: oyama n. Nucl Med Biol. 2012 Oct;39(7):944-7. doi: 10.1016/j.nucmedbio.2012.05.008. Epub 2012 Jul 4. Nucl Med Biol. 2012. PMID: 22766258

7

11C-Acetate PET imaging for renal cell carcinoma.

Oyama N, Okazawa H, Kusukawa N, Kaneda T, Miwa Y, Akino H, Fujibayashi Y, Yonekura Y, Welch MJ, Yokoyama O. Oyama N, et al. Eur J Nucl Med Mol Imaging. 2009 Mar;36(3):422-7. doi: 10.1007/s00259-008-0981-0. Epub 2008 Nov 19. Eur J Nucl Med Mol Imaging. 2009. PMID: 19018529

8

Carbon-11-acetate positron emission tomography (PET), versus fluorine- 18 fluorodeoxyglucose PET and CT for the diagnosis of recurrent prostate cancer after radical prostatectomy in cases of prostate specific antigen of more than 1 to 3ng/mL.

Oyama N, Ito H, Aoki Y, Miwa Y, Akino H, Kudo T, Okazawa H, Fujibayashi Y, Welch M, Yokoyama O. Oyama N, et al. Hell J Nucl Med. 2013 May-Aug;16(2):146-7. Hell J Nucl Med. 2013. PMID: 24032176 No abstract available.

9

Retention mechanism of hypoxia selective nuclear imaging/radiotherapeutic agent cu-diacetyl-bis(N4-methylthiosemicarbazone) (Cu-ATSM) in tumor cells.

Obata A, Yoshimi E, Waki A, Lewis JS, Oyama N, Welch MJ, Saji H, Yonekura Y, Fujibayashi Y. Obata A, et al. Among authors: oyama n. Ann Nucl Med. 2001 Dec;15(6):499-504. doi: 10.1007/BF02988502. Ann Nucl Med. 2001. PMID: 11831397

10

11C-acetate PET imaging of prostate cancer.

Oyama N, Akino H, Kanamaru H, Suzuki Y, Muramoto S, Yonekura Y, Sadato N, Yamamoto K, Okada K. Oyama N, et al. J Nucl Med. 2002 Feb;43(2):181-6. J Nucl Med. 2002. PMID: 11850482 Free article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

452 results

Search Page

Filters